A REIT With Great V...
Health Care: Drugs
Merrimack Pharmaceuticals Inc (MACK: NASDAQ)
$5.11 -0.16 | -3.04%
05/22/13 - 04:00 PM ET
Portfolios with MACK
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks With Big Insider Buy...
- ProTPG-Axon Capital
- ContributorStocks With Big Insider Buy...
- ContributorBreakout Stocks Of The Week...
Latest MACK Headlines from TheStreet
- Merrimack Reports First Quarter 2013 Financial Results 05.13.13 | 10:05 am
- Merrimack To Present At Multiple Investor Conferences This Spring 05.02.13 | 08:05 am
- Merrimack Pharmaceuticals Announces Timing Of First Quarter 2013 Investor Conference Call 04.30.13 | 10:04 am
- Merrimack Pharmaceuticals Completes Enrollment Of Second Cohort In Phase 2 Study Of MM-121 In Non-Small Cell Lung Cancer 04.29.13 | 08:04 am
- Merrimack Pharmaceuticals Getting Very Oversold (MACK) 04.24.13 | 12:04 pm
- Merrimack Pharmaceuticals Completes Enrollment Of One Cohort In Neoadjuvant Phase 2 Study Of MM-121 In HER2-Negative Breast Cancer 04.15.13 | 08:04 am
- Merrimack Pharmaceuticals Announces Webcast Of Inaugural Research & Development Day 04.05.13 | 12:04 pm
- Merrimack Pharmaceuticals Completes Enrollment In A Phase 2 Study Of MM-121 In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers 03.18.13 | 08:03 am
- Merrimack Reports Fourth Quarter And Full Year 2012 Financial Results 03.14.13 | 08:03 am
- 5 Stocks Poised for Breakouts 03.01.13 | 02:03 pm
Press Releases for MACK
- Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model - PR Newswire 04.10.13 | 09:04 am
- Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor - PR Newswire 04.04.13 | 08:04 am
- Merrimack Pharmaceuticals To Present Preclinical Research On Five Novel Cancer Therapies - PR Newswire 04.02.13 | 09:04 am
- Merrimack Pharmaceuticals Presents Promising Phase I Clinical Data For Novel Agent To Treat HER2-positive Breast Cancer And Preclinical Data On Companion Diagnostic - PR Newswire 12.10.12 | 09:12 am
- Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer - PR Newswire 11.27.12 | 09:11 am
- Merrimack Pharmaceuticals' Therapies Show Promise In Certain Advanced Breast, Gastric And Gynecologic Cancers - PR Newswire 10.02.12 | 08:10 am
- Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers - PR Newswire 09.18.12 | 11:09 am
- Merrimack Pharmaceuticals, Inc. Announces Pricing Of Initial Public Offering - PR Newswire 03.28.12 | 11:03 pm
Partner Headlines for MACK
- After Hours Most Active for Nov 16, 2012 : SFD, QQQ, WIN, TSN, MSFT, TSS, BAC, MYL, ZGNX, WM, MACK, MMC - NASDAQ 11.16.12 | 09:11 pm
- Morning Market Losers - Benzinga 09.25.12 | 09:09 am
- 5 Low-Debt Biotech Stocks Forecasted For Growth - Seeking Alpha 09.22.12 | 09:09 am
- Jim Cramer Watchdog: SELL Morgan Stanley and 'BUY, BUY, BUY' These 3 HOT Stocks - Wall St. Cheat Sheet 07.20.12 | 11:07 am
